Early, intensive and long-term statin therapy in acute coronary syndrome: Focus on anti-inflammatory mechanisms

Vascular Disease Prevention

Volumn 2, Issue 3, 2005, Pages 181-186

  Li, Jian Jun ^a   Hu, Sheng Shou ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; ENDOTHELIN 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; LONG TERM CARE; MONOCYTE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

EID: 21744461286     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270054368943     Document Type: Review

References (61)

1. Ross R. Atherosclerosis-an inflammatory discase. N Engl J Med 1999; 340:115126.
2. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the noon. N Engl J Med 1997; 336:1014-1016.
3. Li J-J. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 2004; 63:100-102.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and risks of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
5. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999; 100:1148-1150.
6. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818.
7. Li J-J, Jiang H, Huang CX, et al. Elevated levels of plasma C-reactive protein in patients with unstable angina: Its relations with coronary stenosis and lipid profile. Angiology 2002; 53:265-272.
8. Li J-J, Fang C-H, Huang C-X, et al. Activation of NF-κB and associated with elevated C-reactive protein in patients with unstable angina. Heart Lung Circulation 2004; 13:173-178.
9. Li J-J, Fang C-H, Huang C-X, et al. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology 2004; 55:479-484.
10. Li J-J. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004; 62: 499-506.
11. Li J-J. Silent myocardial ischemia may be related to inflammatory response. Med Hypotheses 2004; 62:252-256.
12. Ferranti SD, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002; 317:1-15.
13. Yusuf S, Reddy S, Ounpuu S, et al. Globe burden of cardiovascular disease: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746-2753.
14. Yusuf S, Reddy S, Ounpuu S, et al. Globe burden of cardiovascular disease: Part 11: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104:2855-2864.
15. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998; 98:2219-2222.
16. Schwartz RS, Bayes-Genis A, Lesser JR, et al. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J Intervent Cardiol 2003; 16:231242.
17. Muller JE, Abela GS, Nesto RW, et al. Triggers, acute risk factors and vulnerable plaque: the lexicon of a new frontier. J Am Coll Cardiol 1994; 23:809-813.
18. Li J-J, Chen X-J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein as well as lipopolysaccharide. Coron Artery Dis 2003; 14:329-334.
19. Li J-J. Rapid effects on lipid profile and C-reactive protein by simvastatin in patients with hypercholesterolemia. Clin Cardiol 2003; 26:472-476.
20. Li J-J, Fang C-H. Effect of a single high-dose of simvastatin on C-reactive protein in patients with unstable angina. Heart Drug 2004; 4; In press.
21. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103:1191-1193.
22. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447-52.
23. Ridker PM, Rifai N, Pfeffer MA, et al. for the cholesterol and recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100:230-235.
24. Fang C-H, Li J-J. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses 2001; 64:192-196.
25. Ostadal P, Alan D, Hajek P, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem 2003; 246:45-50.
26. Lefer DJ, Scalia R, Jones SP, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100:178-184.
27. Diomede L, Albain D, Sottocorno M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-1332.
28. Kimura M, Kurose I, Rusell J. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17:1521-1526.
29. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE investigators. Ann Intern Med 2004; 140:923-924.
30. Wang H-R, Li J-J, Huang C-X, Jiang, H. Fluvastatin inhibits the expression of tumor necrosis-a and activation of nuclear factor-kB in endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005; 353:53-60.
31. Li J-J, Fang C-H, Hui R-T. Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 levels in patients with stable angina. Clin Chim Acta 2005; 354: 205-208.
32. Stalker TJ, Lefer AM, Scalla R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133:406-412.
33. Sparrow CP, Burton CA, Hernandez M. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21:115-121.
34. Maggard MA, Ke B, Wang T. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 1998; 65:149-155.
35. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decrease mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001; 66:155-162.
36. Cosentino F. Statin in cardiovascular disease: role of Rho/Rho kinase inhibition and of Akt activation. Recenti Prog Med 2003; 94:444-450.
37. Xu ZM, Zhao SP, Li QZ, et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003; 338:17-24.
38. Heeschen C, Hamm CW, Laufs U, et al. Withdrawl of statins increase events rate in patients with acute coronary syndromes. 2002; 105:1446-1452.
39. Fairhurst K, Huby G. From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ 1998; 317:1130-1134.
40. Azar RR, Waters DD, Lebanon B. PRINCE'S prospects: statin, inflammation, and coronary risk. Am Heart J 2001; 141:881-883.
41. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
42. Schrott HG, Knapp H, Davila M, et al. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. Am Heart J 2000; 140:249-252.
43. Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MlRACL) study. Circulation 2004; 110:386-391.
44. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19:540-556.
45. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Design 2003; 9:2425-2443.
46. Eagle KA, Kine-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117:73-81.
47. Jackson G. The role of statins in acute coronary syndromes: managing the unmet need. Int J Clin Pract 2000; 54:445-449.
48. Szucs TD. Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price? Eur Heart J 1998; 19 (suppl M): M22-M28.
49. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140:857-866.
50. Kinlay S. Early statin therapy in acute coronary syndromes. Minerva Cardioangiol 2003; 51:557-584.
51. Langer A, Constance C, Fodor JG, et al. Statin therapy and the management of acute coronary syndromes. Can J Cardiol 2003; 19:921-927.
52. Paradiso-Hardy FL, Gordon WL, Jackevicius CA, et al. The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 2003; 23:506-513.
53. Pepine CJ. Optimizing lipid management in patients with acute coronary syndromes. Am J Cardiol 2003; 91(4A):30B-35B.
54. Spin JM, Vagelous RH. Early use of statins in acute coronary syndromes. Curr Atheroscler Rep 2003; 5:44-51.
55. Reinhardt SC, Vaughan CJ. Statins in acute coronary syndromes. Drug Today 2002; 38:339-350.
56. Rosenson RS, Brown AS. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr Opin Lipidol 2002; 13:625-630.
57. Bybee KA Wright RS, Kopecky SL. Effect of early statin therapy after acute coronary syndromes: a concise review of recent data. Cardiol Rev 2002; 10:301-305.
58. For the pravastatin or atorvastatin evaluation infection therapy-thrombolysis in myocardial infarction. 22 investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms. Obstet Gynecol Surv 2004; 59:522-524.
59. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1562-1564.
60. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1566.
61. Correia LC, Sposite AC, Lima JC, et al. Anti-inflammatory effect of atorvastatin (80mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 203; 92:298-301.